Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. (Q50909590)

25 March 2018

title

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. (English)

1 reference

25 March 2018

main subject

patient

0 references

hepatocellular carcinoma

1 reference

Fumitaka Arihara

1

1 reference

25 March 2018

Eishiro Mizukoshi

2

1 reference

25 March 2018

Masaaki Kitahara

3

1 reference

25 March 2018

Yoshiko Takata

4

1 reference

25 March 2018

Kuniaki Arai

5

1 reference

25 March 2018

Tatsuya Yamashita

6

1 reference

25 March 2018

Yasunari Nakamoto

7

1 reference

25 March 2018

Shuichi Kaneko

8

1 reference

25 March 2018

publication date

14 June 2013

1 reference

25 March 2018

Cancer Immunology, Immunotherapy

published in

1 reference

25 March 2018

volume

62

1 reference

25 March 2018

issue

8

1 reference

25 March 2018

page(s)

1421-1430

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1007/s00262-013-1447-1

exact match

0 references

cites work

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Immunotherapeutic strategies for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

An essential role for Scurfin in CD4+CD25+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Stat proteins and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1447-1

10.1007/S00262-013-1447-1

21 January 2018

Identifiers

DOI

1 reference

25 March 2018

PubMed ID

23764929

1 reference

25 March 2018